Johnson & Johnson's INLEXZO Delivers 74 Percent Disease-Free Survival at One Year in BCG-Unresponsive, High-Risk, Papillary-Only NMIBC
December 06, 2025
December 06, 2025
RARITAN, New Jersey, Dec. 6 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson's INLEXZO(TM) (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bla . . .
* * *
Johnson & Johnson's INLEXZO(TM) (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bla . . .